To address this knowledge gap, our study was designed to investigate two key questions: Whether Fas/RIPK1 co-overexpression occurs in human EMs lesions; Whether CUR can directly engage Fas/RIPK1 to modulate their activity, providing novel therapeutic insights for EMs management. The gene discussed is RIPK1; the disease is eosinophilia-myalgia syndrome.